重连成瘾中的奖赏环路:药物使用障碍脑深部电刺激与毁损入路的系统综述
该系统综述纳入47项人体研究,评估靶向奖赏网络节点的DBS与毁损术治疗物质使用障碍。最明确的对照证据来自双侧伏隔核DBS治疗重度酒精使用障碍:一项随机延迟激活试验(n=12)显示戒酒天数从27.6%增至6个月56.0%(p=0.014)和18个月74.2%(p=0.004)。总体数据支持临床合理性与试验设计依据,但尚不能确定对各亚型的确切疗效。
要点
- 双侧伏隔核DBS对重度酒精使用障碍显示最明确的对照信号。
- 阿片/海洛因及多物质使用障碍的DBS证据有前景但确定性较低。
- 毁损术证据受不可逆性、随访异质性和神经心理代价限制。
核心结论
- DBS与毁损术应视为不同的神经外科模态而非单一治疗类别。
- 当前最强对照人体信号来自双侧伏隔核DBS治疗重度酒精使用障碍。
- 阿片/海洛因及多物质使用障碍的DBS证据存在但确定性较低。
- 毁损术提供历史与机制支持,但不可逆性、随访异质性和神经心理代价要求更高证据与伦理门槛。
- 现有数据支持临床合理性与试验设计依据,但不足以确定对各物质使用障碍亚型的确切疗效。
研究设计与样本
- 系统检索PubMed、PubMed Central、Embase和Scopus(建库至2025年9月9日)。
- 纳入报告可提取结局的人体DBS/消融研究,靶向成瘾相关节点(如伏隔核、腹侧内囊/腹侧纹状体/内囊前肢、丘脑底核)。
- 纳入在体成瘾模型动物研究以提供机制背景。
- 共47项研究符合纳入标准,结果采用叙述性综合。
主要发现
- 唯一随机延迟激活试验(n=12)中,双侧伏隔核DBS使戒酒天数从27.6%增至6个月56.0%(p=0.014)和18个月74.2%(p=0.004)。
- 同一试验中重度饮酒天数从69.6%降至6个月47.4%(p=0.020)和18个月35.5%(p=0.031),渴求OCDS从21.0降至6个月10.5(p=0.014)和18个月5.9(p=0.008)。
- 开放标签酒精DBS试点中每日饮酒量从10.4降至12个月2.7(p<0.05),OCDS从28.7降至8.3(p<0.05)。
- 海洛因使用障碍DBS靶向伏隔核±内囊前肢(n=8)中5/8保持戒断>3年,渴求VAS从7.6降至3个月1.4和24个月0.8(p<0.001)。
- 多物质可行性研究(n=4)中两人分别保持戒断>1150天和>520天,阿片渴求p=0.036、苯二氮䓬类渴求p=0.001。
关键数值与推荐
- 酒精使用障碍随机试验中盲法阶段分离支持早期刺激对戒酒/重度饮酒天数更优(p=0.048)。
- 海洛因使用障碍DBS组抑郁症状HDRS从12.4降至3.4(p=0.001)。
- 生物标志物引导的阿片DBS降低线索诱发渴求(6.93 vs 3.09;p<0.001)。
- 酒精伏隔核毁损队列中3/12复发,依赖严重度从39.08降至9.25(p<0.01),4年总体戒断率53.8%。
临床怎么用
- 对于重度难治性酒精使用障碍,双侧伏隔核DBS是目前对照证据最强的试验性选择。
- 阿片/海洛因及多物质使用障碍可考虑DBS但应告知证据确定性较低。
- 毁损术因不可逆性和神经心理代价,需更高证据与伦理门槛方可临床采用。
- 未来试验设计应区分DBS与毁损术,并按物质类型和靶点分层。
局限性
- 人体文献在靶点、模态和结局上碎片化,限制靶点选择与试验设计。
- 多数证据来自小样本、开放标签或非对照研究。
- 毁损术队列随访异质性大,长期复发与神经心理代价报告不一。
- 临床前研究显示强靶点和状态依赖性,包括酒精依赖模型中矛盾性复发增强。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Neurosurgical modulation of reward circuitry has been explored for severe, treatment-refractory substance use disorders (SUDs), yet the human literature remains fragmented across targets, modalities, and outcomes, limiting target selection and future trial design. We systematically reviewed human clinical evidence for deep brain stimulation (DBS) and lesion approaches targeting reward network nodes for SUDs, and summarized convergent preclinical findings to identify where the strongest clinical signal exists and to provide a framework for mechanism-informed future trials. METHODS: We systematically searched PubMed, PubMed Central, Embase, and Scopus (inception-September 9, 2025) for human DBS/ablation studies in primary SUDs targeting addiction-relevant nodes (e.g., nucleus accumbens [NAc], ventral capsule/ventral striatum/anterior limb of internal capsule [ALIC], subthalamic nucleus) and reporting extractable outcomes; in vivo addiction-model animal studies were included for mechanistic context. Findings were synthesized narratively. RESULTS: Forty-seven studies met inclusion criteria. The clearest controlled human signal came from bilateral NAc DBS in severe alcohol use disorder, with additional promising but less mature findings in heroin/opioid DBS. In the only randomized delayed-activation trial of bilateral NAc DBS for severe alcohol use disorder (n = 12), abstinent days increased from 27.6% to 56.0% at 6 months (p = 0.014) and 74.2% at 18 months (p = 0.004), and heavy drinking days decreased from 69.6% to 47.4% (p = 0.020) and 35.5% (p = 0.031). Craving improved (OCDS 21.0 to 10.5 at 6 months, p = 0.014; 5.9 at 18 months, p = 0.008), with blinded-phase separation favoring earlier stimulation for abstinent/heavy drinking days (p = 0.048). An open-label alcohol DBS pilot reported drinks/day decreasing from 10.4 to 2.7 at 12 months (p < 0.05) and OCDS from 28.7 to 8.3 (p < 0.05). In heroin use disorder DBS targeting NAc ± ALIC (n = 8), 5/8 remained abstinent for > 3 years; craving VAS decreased from 7.6 to 1.4 at 3 months and 0.8 at 24 months (p < 0.001), with depressive symptoms improving (HDRS 12.4 to 3.4; p = 0.001). In a polysubstance feasibility study (n = 4), two participants maintained abstinence for > 1150 and > 520 days; craving decreased in individuals (opioid craving p = 0.036; benzodiazepine p = 0.001). Biomarker-guided opioid DBS reduced cue-induced craving (6.93 vs 3.09; p < 0.001). Ablation cohorts showed short-term improvements (alcohol NAc ablation: 3/12 relapsed; dependence severity 39.08 to 9.25, p < 0.01), but longer-term relapse and neuropsychological tradeoffs were reported (4-year abstinence 53.8% overall). Preclinical studies highlighted strong target-and state-dependence, including paradoxical relapse augmentation in alcohol-dependent models. CONCLUSION: DBS and lesion approaches should be interpreted as distinct neurosurgical modalities rather than a single therapeutic class. The strongest controlled human signal currently comes from bilateral NAc DBS in severe alcohol use disorder, with additional but lower-certainty DBS evidence in opioid/heroin and polysubstance use disorders. Lesion approaches provide historical and mechanistic support for the relevance of ventral striatal circuitry, but their irreversibility, heterogeneous follow-up, and neuropsychological tradeoffs require a higher evidentiary and ethical threshold. Overall, current data support clinical plausibility and trial-design rationale, but not definitive efficacy across SUD subtypes.
引用
- Levin-Carrion Y, Riestra JM, Campbell T, et al. Rewiring reward in addiction: a systematic review of human evidence for deep brain stimulation and lesion approaches in substance use disorders. Acta Neurochir (Wien). 2026. PMID: 42446584. doi:10.1007/s00701-026-06979-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。